Letolizumab
Product Specifications
UNSPSC Description
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time[1][2][3].
Target Antigen
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/letolizumab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Letolizumab]
References & Citations
[1]Karnell JL, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2019 Feb 15;141:92-103. |[2]Kim SC, et al. Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. Am J Transplant. 2017 May;17(5):1182-1192.|[3]Spicer P, et al. Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future. Expert Opin Investig Drugs. 2019 Feb;28(2):99-106.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99701/Letolizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99701/Letolizumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1450981-87-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
